Business Context and Reporting Period
Compugen Ltd., a drug and diagnostic discovery company, reported financial results for the third quarter ended September 30, 2005, via Form 6-K filed on November 2, 2005. The company utilizes predictive models and discovery engines to develop therapeutic proteins and diagnostic markers. Effective September 1, 2005, Alex Kotzer assumed the position of President and Chief Executive Officer.
Key Financial Metrics
| Metric | Q3 2005 | Q3 2004 | 9 Months 2005 | 9 Months 2004 |
|---|---|---|---|---|
| Total Revenues and Grants | $761,000 | $971,000 | $2.1 million | $3.5 million |
| Governmental and Other Grants | $666,000 | $326,000 | $1.5 million | $1.0 million |
| Net Loss | $3.6 million | $3.6 million | $10.6 million | $10.0 million |
| Net Loss Per Share | ($0.13) | ($0.13) | ($0.38) | ($0.36) |
| Cash and Marketable Securities | $38.0 million (as of Sept 30, 2005) | N/A | N/A | N/A |
Liquidity and Balance Sheet: As of September 30, 2005, total assets were $43.99 million, down from $55.35 million at year-end 2004. Total shareholders' equity was $39.41 million. Current liabilities totaled $2.25 million.
Material Changes Versus Prior Period
- Revenue Decline: Total revenues and grants for Q3 2005 decreased 22% compared to Q3 2004, driven by a drop in non-grant revenue from $645,000 to $95,000. However, governmental grants increased significantly from $326,000 to $666,000.
- Operating Expenses: Total operating expenses decreased slightly in Q3 2005 ($4.53 million) compared to Q3 2004 ($4.74 million), primarily due to reductions in sales and marketing and general and administrative expenses, partially offset by higher research and development costs.
- Cash Position: Cash, cash equivalents, and marketable securities decreased by $3 million from June 30, 2005, to September 30, 2005.
Outlook, Risks, and Management Commentary
Management emphasized the company's focus on developing and commercializing potential biomarkers and therapeutic proteins derived from its predictive research capabilities. The appointment of Alex Kotzer is intended to leverage his experience in managing biotech operations to advance the company's diagnostic and therapeutic product candidates.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Identified risks include changes in relationships with collaborators, the impact of competitive products and technological changes, risks relating to the development of new products, and the ability to implement technological improvements.
Investor Verification Checklist
- Verify the sustainability of governmental and other grants, which comprised 87% of total revenue in Q3 2005.
- Confirm the burn rate and runway given the $3 million cash decrease in Q3 and the continued net loss of $3.6 million for the quarter.
- Assess the progress of the early-stage in-house pipeline and the status of out-licensed discoveries.
- Review the impact of the new CEO leadership on strategic direction and operational efficiency.